Q-omics provides the consensus-scored HCG25 profile across patient tissues and cancer cell-line models. HCG25 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HCG25 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, HCG25 RNA expression shows 19,677 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where HCG25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCG25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCG25 survival associations across molecular data types. HCG25 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCG25 RNA expression–survival associations across cancer types. High HCG25 expression shows unfavorable associations in KIRC, ACC, LIHC, COAD and KICH, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for HCG25 RNA expression.
This table summarizes HCG25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HCG25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCG25 shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, KIRC, LIHC and LUSC. The HNSC box plot shows higher HCG25 RNA expression in tumor versus normal tissue (log2 FC = +0.382, t-test p < 0.001).
This table shows molecular features associated with HCG25 in patient tissues and cancer cell lines. In patient samples, HCG25 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
